Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

75 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Facts and controversies in the use of trastuzumab in the adjuvant setting.
Dinh P, de Azambuja E, Cardoso F, Piccart-Gebhart MJ. Dinh P, et al. Nat Clin Pract Oncol. 2008 Nov;5(11):645-54. doi: 10.1038/ncponc1219. Epub 2008 Sep 9. Nat Clin Pract Oncol. 2008. PMID: 18779850 Review.
An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.
Piccart-Gebhart MJ, Bruning P, Gamucci T, Klijn J, Roy JA, Awada A, Kusenda Z, Van Vreckem A, Paridaens R. Piccart-Gebhart MJ, et al. Semin Oncol. 1996 Oct;23(5 Suppl 11):11-5. Semin Oncol. 1996. PMID: 8893893 Clinical Trial.
Herceptin: the future in adjuvant breast cancer therapy.
Piccart-Gebhart MJ. Piccart-Gebhart MJ. Anticancer Drugs. 2001 Dec;12 Suppl 4:S27-33. doi: 10.1097/00001813-200112004-00005. Anticancer Drugs. 2001. PMID: 11989524 Review.
[Breast cancer treatment in 2004: towards a tailored approach].
Nogaret JM, Bernard-Marty Ch, Mancini I, Piccart-Gebhart M. Nogaret JM, et al. Rev Med Brux. 2004 Sep;25(4):A394-403. Rev Med Brux. 2004. PMID: 15516078 Review. French.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Piccart-Gebhart MJ, et al. N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306. N Engl J Med. 2005. PMID: 16236737 Clinical Trial.
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ; HERA study team. Smith I, et al. Lancet. 2007 Jan 6;369(9555):29-36. doi: 10.1016/S0140-6736(07)60028-2. Lancet. 2007. PMID: 17208639 Clinical Trial.
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M. de Azambuja E, et al. Br J Cancer. 2007 May 21;96(10):1504-13. doi: 10.1038/sj.bjc.6603756. Epub 2007 Apr 24. Br J Cancer. 2007. PMID: 17453008 Free PMC article.
Trastuzumab (herceptin) for early-stage breast cancer.
Ismael G, Rosa DD, de Azambuja E, Braga S, Piccart-Gebhart M. Ismael G, et al. Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56. doi: 10.1016/j.hoc.2007.03.003. Hematol Oncol Clin North Am. 2007. PMID: 17512447 Review.
75 results
Jump to page
Feedback